塞来昔布影响聚蛋白多糖酶在骨关节炎患者血清中的表达  

EXPRESSION OF AGGRECANASE AFFECTED BY CELECOXIB IN SERUM WITH OSTEOARTHRITIS

作　　者：刘甬民[1] 冯智英[1] 顾鹏程[2] 章沿锋[1] 林向进[2] 祝胜美[1] 

机构地区：[1]浙江大学医学院附属第一医院麻醉科,杭州310003 [2]浙江大学医学院附属第一医院骨科,杭州310003

出　　处：《中国疼痛医学杂志》2011年第11期670-673,共4页Chinese Journal of Pain Medicine

基　　金：浙江省卫生厅医药卫生科学研究基金资助项目(2009A63)

摘　　要：目的:探讨塞来昔布对中晚期骨关节炎(OA)患者关节软骨中聚蛋白多糖酶1(aggre-canase-1,Agase-1或ADAMTS-4)及基质金属蛋白酶组织抑制因子(tissue inhibitor of metalloprotein-ase 3,TIMP-3)表达的影响。方法:21例拟接受全膝关节置换术的单关节OA患者为实验组,入院前2个月已连续服用塞来昔布200mg,每日2次,入院后继续服用持续1周直至术前;将因外伤导致膝关节损伤的急诊患者作为空白对照组(18例)。应用酶联免疫吸附试验(ELISA)检测Agase 1、TIMP-3在两组血清中的表达,以浓度表示其在血清中的水平。甲苯胺蓝法检测关节软骨中蛋白多糖(PG)的含量。结果:与对照组相比,实验组Agase-1表达水平无明显变化(P>0.05),而TIMP-3明显增加(P<0.01),同时关节软骨中的蛋白多糖含量增加(P<0.05)。结论:塞来昔布通过增加TIMP-3的表达,从而抑制Agase 1的活性,减缓OA患者关节软骨中蛋白多糖的降解。Objective ： To detect the effect of celecoxib on the expression of aggrecanase-1（Agase-1） and tissue inhibitor of metalloproteinase-3（TIMP-3） in the serum of late osteoarthritis（OA） patients.Methods： 39 cases were divided into celecoxib-treated group（n = 21） who received total knee replacement surgery with celecox-ib for 8 weeks and control group（n = 18） of emergency surgery of knee without celecoxib. Celecoxib was given orally twice a day after admission until the day before operation.Expression of Agase-1 and TIMP-3 concentration in the two groups were investigated by enzyme-linked immunosorbent assay（ELISA） and represented by ng/ml.Changes of proteoglycan（PG） in cartilage were analysed by toluidine blue method.Results ： Expressions of Agase-1 have no difference between two group（P 0.05）.Compared to control group,the serum levels of TIMP-3 and PG in cartilage in celecoxib-treated group increased significantly（P 0.01）.Conclusion ： Celecoxib can increase PG expression in cartilage by upregulation of TIMP-3 which can inhibit Agase-1 activity.

关 键 词：聚蛋白多糖酶 基质金属蛋白酶组织抑制因子 骨关节炎 环氧化酶-2 

分 类 号：R684.3[医药卫生—骨科学]